Foghorn Therapeutics Inc. (FHTX) Tops Q2 EPS by 15c

Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q2 EPS of ($0.10), $0.15 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $7.59 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.

You May Also Be Interested In

• Andersen Group Inc. (ANDG) Reports Q2 Loss of $0.09; offers guidance
• Bitgo Holdings, Inc. (BTGO) Reports Q2 Loss of $0.16
• Cerebras Systems Inc. (CBRS) Misses Q2 EPS by $2.80, Misses on Revenue; Offers FY26 Revenue Guidance